By Cristina Roca

Sanofi SA and GlaxoSmithKline PLC said Wednesday that a single booster dose of their Covid-19 vaccine candidate delivered consistently strong immune responses.

Preliminary results from a clinical trial looking at the safety and immunogenicity of the booster shot showed that neutralizing antibodies increased regardless of whether participants had been initially vaccinated with the shot made by AstraZeneca PLC, by Pfizer Inc. and BioNTech SE or by Moderna Inc., the two pharmaceuticals companies said.

The Omicron variant of the coronavirus wasn't circulating during the trial, but the companies are now testing the ability of the shot to cross-neutralize against it, they said.

"This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination," the companies said.

A Phase 3 trial for the vaccine is still under way, with results expected in the first quarter of 2022.

Write to Cristina Roca at cristina.roca@wsj.com

(END) Dow Jones Newswires

December 15, 2021 02:10 ET (07:10 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Sanofi Charts.